Details of Technology:
Inflammation causes eosinophils in the lungs to produce nitric oxide, which is then released in exhaled breath. It reacts with atmospheric trioxygen in a chemiluminescence reaction to become nitrogen dioxide, emitting light as it transitions from an excited to a ground state. This emitted light is proportional to the amount of exhaled nitric oxide, which reflects the amount of underlying lung inflammation and is the basis for the clinical application. Three separate devices to measure this exhaled nitric oxide have been evaluated by NICE and are the most widely used: NObreath, NIOX VERO and NIOX MINO.
NIOX MINO is a hand-held portable device manufactured by Aerocrine that uses an electrochemical sensor to analyse the concentration of exhaled nitric oxide. It requires a ten second exhalation with the last 3 seconds of exhaled breath being analysed. It is accurate to +/-5ppb and precise to <3ppb of measured value <30ppb or <10% of measured value ≥30ppb (10, 11) . NIOX MINO has been validated for both school-age children and adults. In pre-school children where co-ordinated or prolonged exhalation is difficult, offline exhaled breath has been collected in bags and measured, though this is not its recommended use. The machine can self-calibrate, although Aerocrine recommend the sensor is changed yearly. NIOX MINO must be plugged into a power outlet and has a minimum instrument 'shelf-life' of 3 years. It costs £2,468 (all quoted prices inclusive of VAT) and an additional £4.93 -£9.35 per test for the sensor and filter, depending on the quantity bought (12). Aerocrine's upgrade on the NIOX MINO, the NIOX VERO, comes with a rechargeable battery pack that charges in under 8 hours and will last for up to 30 measurements per charge with a battery life of around one year and a guaranteed device operational life of 5 years (12). The NIOX VERO costs £2,540 for the instrument and an additional £4.62 -£8.75 per test. Previous NIOX systems have also been used in some studies, such as NIOX FLEX, which used similar technology but was a desktop computer based system. These have now largely been replaced by the cheaper, more accurate versions above and are therefore not included in NICE guidelines.
NObreath is the Bedfont Scientific equivalent and is also a hand-held, battery powered device. It requires a 12 second breath exhalation in adults and 10 seconds in children, is sensitive to +/-5ppb, works between temperatures of 10-30°C and takes under a minute to warm up to use. It costs £1,794.00 (13) with similar additional costs to NIOX MINO for test equipment.
There are other desktop-based models on the market but these have not been included in the current NICE guidelines. Although the reason for this is not stated, NICE seem to have focused on the most studied models and excluded some of the older or less portable devices. Ecomedics have an Analyser CLD 88 sp model that is a computer desktop based system, with options of single or multiple breath options to aid use when patients are unable to co-ordinate their breathing as required. Yearly service and maintenance is recommended. General Electric Company manufacture the desktop Sievers Nitric Oxide Analyser (NOA 280i), which offers a range of NO collection devices, including nasal sampling and offline bag collection of exhaled breath for later analysis. It is accurate to +/-5ppb and requires servicing every 6 months.
Patient Group and Use:
• Reducing children's risk of future asthma exacerbations by optimisation of steroid dosing • Helping guide physicians in deciding between increasing steroid dose versus addition of long acting bronchodilator at Step 3 of asthma treatment ladder.
Importance:
An estimated 300 million people worldwide have asthma and up to 250,000 die prematurely each year, as many as 90% of which are thought to be avoidable (14) . In the UK 1 in 11 children have asthma (15) , in the USA 14% of children are diagnosed with asthma and in Western Europe 6.2% of 13-14 year-olds reported severe asthma in a 12 month period (16, 17) . Asthma is directly linked to 4.1 million GP consultations and over 25,000 paediatric hospital admissions per year in the UK, costing the NHS over £1 billion per year. The National Review of Asthma Deaths (NRAD) 2014 found that 57% of those who died from asthma were under primary care supervision only and in 46% of the deaths in the study period, factors were identified in terms of implementation of asthma guidelines that could have made death less likely (18) . Of those who died where prescription data was available, 39% (65/165) had been prescribed over 12 short-acting reliever inhalers in the previous year and 4% (6/165) over 50, reflecting a pattern of excessive use of reliever medication. Conversely preventer medication appeared under-prescribed with 80% not collecting the recommended 12 preventer inhalers per year and 38% using under 4 preventer inhalers in a 12 month period (18) . Clinicians need to improve their assessment of future asthma risk and tend to over-focus on current quality of life, reflected in these prescribing patterns. Equally those on regular ICS should be reviewed and appropriately stepped down when well controlled, given the risks of excessive steroid use in asthma, including increased risk of lower respiratory tract infections (19) . Finding more reliable ways of monitoring asthma could therefore improve control to reduce both morbidity and mortality as well as reduce the number of children being over treated.
Previous Research:

Impact compared to existing technology
Characteristics of included studies Table 1 summarises the study characteristics of the nine RCTs we identified that assessed the relationship between FeNO monitoring in asthmatic children and their asthma control. The study outcomes included the number of acute asthma exacerbations, changes in dosage of inhaled corticosteroids and asthmarelated quality of life. All nine RCTs were conducted in secondary care, predominantly in Western Europe, enrolled patients with a range of asthma severities and used sample sizes ranging from 47 to 546 participants. Aerocrine manufactured NIOX equipment was used in seven studies (20) (21) (22) (23) (24) (25) (26) . Six studies involved run-in periods ranging from 2 to 16 weeks to stabilise treatment before randomisation (20) (21) (22) (25) (26) (27) . In six studies children were specifically recruited with a history of allergic asthma, usually confirmed as RAST 2 positive to at least one airborne allergen and in some cases with additional positive IgE or skin prick test (20) (21) (23) (24) (26) (27) (28) . In two of the three studies where participants were not allergy tested there was a significantly increased use of ICS in the FeNO groups by the end of the study, although neither study found any related improvement in quality of life or significant reduction in exacerbations (25, 27) .
Asthma exacerbations were defined in a variety of ways, with most studies using hospital admission, unplanned review or need for oral steroids (20) (21) (22) (23) 26) . All except one study (26) used a local guideline-based symptom score as their comparator and most included symptom control scores into their treatment algorithm (21) (22) (23) (24) (25) (26) . Most studies have taken a pragmatic approach and added FeNO to standard care so that in all but two studies a step down in treatment would not be done when the FeNO alone was low if symptoms remained uncontrolled (21) (22) (23) (24) (25) (26) (27) . In one study treatment would actually still be increased in the intervention arm irrespective of the FeNO result if control was deemed to be poor (26). 
Impact on number of asthma exacerbations
Two studies reported that FeNO-guided management was associated with fewer participants experiencing one or more exacerbations of asthma (24, 27) . However, only one of these studies also reported a significantly lower rate of exacerbations among participants in the FeNO group (24) . This study (24) defined exacerbations based on symptom criteria stated by GINA guidelines, whereas the other (27) defined exacerbations as episodes requiring prescription of oral steroids, with or without hospital admission.
One study did not observe a significant difference between FeNO and non FeNO groups in the proportion of participants who had one or more exacerbation, but did report that fewer children in the FeNO group were prescribed one or more courses of oral steroids (32.1%, 95% CI 25.3% to 36.7%) than in the comparator group (42.0% 95% CI 35.1% to 47.4%; mean difference -10.3, 95% CI -18.5 % to -2.2%, p=0.0137) (25) . In another study, 8 courses of oral prednisolone were prescribed in 7/42 participants who received FeNOguided management, compared to 18 courses of oral prednisolone prescribed to 10/47 participants who received symptom-guided management (21) . However, this difference was not statistically significant (p=0.60), possibly because six children in the group who received symptom-guided management were prescribed multiple courses of prednisolone, compared to only one child in the FeNO group.
The remaining study which collected data on asthma exacerbations reported a longitudinal reduction in mean exacerbation frequency from baseline after six months and 12 months, but did not perform any formal comparisons between the FeNO-and guideline-based management groups at either follow-up stage (28). Based on prescription of oral steroids, eight exacerbations occurred in the FeNO group compared to 18 in the group who received symptom guided management. However, the difference between groups was not statistically significant (p=0.60). One participant randomised to FeNO-guided management, was hospitalised due to a severe asthma exacerbation.
Szefler et al. 2008 (25)
Any one or more of: 
Verini et al. 2010 (28)
1. Episode of cough, dyspnoea, and wheeze as per ATS-ERS criteria, requiring short-acting β2-adrenergic agonist.
Significant longitudinal reductions in mean exacerbation frequency from baseline were observed after 6 months and 12 months in the FeNO group (baseline 1.96 ± 1.18; 6 months 1.01 ± 0.96, p=0.0003; 12 months 0.83 ± 0.98, p=0.0001). However, no comparisons between the FeNO and non FeNO groups were made at either follow-up stage.
Abbreviations in table-FeNO = fractional exhaled nitric oxide, CI = Confidence Interval, GINA = Global Initiative for Asthma , ATS-ERS= American Thoracic Society and European Respiratory Society
Impact on inhaled corticosteroid prescriptions
Four studies reported a significantly higher final ICS dose in the FeNO group of between 100mcg to 200mcg above that in the comparator (24) (25) (26) (27) . Three of these four studies showed a reduction in exacerbations, suggesting appropriately targeted ICS use will have a therapeutic effect (24, (26) (27) . Two studies saw a similar decrease in ICS dose in both intervention and comparator arms (20, 23) and two showed no change in dose in either arm (21) (22) . In all four of these studies there was no significant change in exacerbation frequency or measures of asthma control. One study showed no change in dose in the FeNO arm, but an increase in ICS in the comparator arm, though there was a reduction in the incidence of exacerbations in the FeNO arm whilst not in the comparator arm (28).
There was a wide variation in the FeNO threshold to step-up treatment, ranging from 10ppb to 50ppb and an association between this threshold value and the subsequent ICS dose. Four of the five studies with a lower threshold of ≥20ppb to step-up treatment saw an increase in ICS dose in the FeNO group (24) (25) (26) (27) . The four studies with the highest FeNO threshold (≥25ppb for step-up) all saw either a reduction or no change in ICS dose and no change in outcomes between the FeNO group and the control (20-23).
Impact on asthma-related quality of life
Four studies used either the Paediatric Asthma Quality of Life Questionnaire (PAQLQ) or the Paediatric Asthma Caregiver Quality of Life Questionnaire (PACQLQ) (20, (22) (23) 27) , with two using both (20, 27) . There was no significant difference in any of these results between the FeNO and comparator groups on asthmarelated quality of life.
Impact on cost effectiveness
An economic evaluation was conducted alongside a randomised control multi-centre trail to assess costeffectiveness of 4-monthly monitoring using FeNO, compared with web-based monthly monitoring and standard care in children with asthma in Netherlands (29) . The trail had a 1 year follow up and the sample size was 272. Patients' health related quality of life was measured using the EQ-5D-3L and Quality Adjusted Life Years (QALYs) were calculated using the area under curve method based on the Dutch tariff of EQ-5D. Costs were assessed from both health care and societal perspectives using a cost questionnaire. No statistically significant differences were found in QALYs and costs between FeNO, web-based monitoring and standard care. From a health care perspective, the FeNO-based strategy was 20% likely to be the most cost effective at a willingness to pay threshold of €40,000 per QALY compared to the other two. On the other hand, from a societal perspective, the FeNO-bases strategy was favoured over a wide range of willingnessto-pay values and had the highest chance (83%) of being most cost-effective at a willingness to pay of about €40 000/QALY. This study showed that FeNO-based strategy could potentially be a cost effective way to monitor children's asthma especially compared with standard care.
Accuracy compared to existing technology
Only the Szefler et al. study documents both the percentage of well controlled patients and their FeNO scores (25) . They reported that 57.3% (306/534) were well controlled for 80% or more of the study period but despite this only 35.6% of participants had FeNO levels <20 ppb on 80% or more of their visits (25) , again raising the issue of the best FeNO threshold for treatment adjustment, but also whether the current measures of control are accurately detecting those who are sub-optimally controlled. Few studies have correlated their findings with other potential markers of airway inflammation but where they do, there is some evidence to show that there is a corresponding reduction in IL-5 with a reduced FeNO (30), although this was not always replicated in other studies (31) .
In one study where re-calibration of the FeNO device was done after the studies were complete, there was evidence of 'drift outside the manufacturer's specification', but this was not significant enough to alter the subsequent treatment decision (23) . The reproducibility of the FeNO scores have not been documented in these studies, however the ease of use of the machines means that the test can be easily repeated at point of testing to improve reliability by taking a consistent plateau NO measurement (26) . Although rarely commented on, the extremely low drop-out rate across the studies suggest that the FeNO measurement has good acceptability.
Guidelines and recommendations
The latest NICE guidelines have recommended the use of FeNO alongside other investigations to help correctly identify asthma when there is diagnostic uncertainty (32, 33) . NICE also suggest it should be used where patients remain symptomatic despite ICS to help guide treatment decisions (33) . They recommend a cut-off of 19-21ppb based on previous studies, but recognise that sensitivities have been quoted from between 49% and 86% for this range. NICE have yet to recommend FeNO should be used for routine monitoring of asthma in children as there is currently insufficient evidence to support this. The American Thoracic Society suggest that FeNO may have benefits over more established tests such as FEV1 reversibility in identifying eosinophilic airway inflammation and those likely to benefit from ICS, monitoring therapeutic response to ICS, and helping identify non-adherence to ICS treatment (34) . SIGN guidelines recognise there is some evidence to suggest FeNO may help guide ICS use, but recommend the evidence is not robust enough to support routine use at this stage and suggests further research is required (2).
Research Questions:
1. What is the optimal FeNO level cut off to use for step-up and step-down in treatment? 2. What other factors can influence measured FeNO levels? 3. How can FeNO be incorporated into monitoring strategies to improve asthma control? 4. Is measurement of FeNO in primary care a cost-effective addition to current management?
Suggested next steps:
Further investigation to establish FeNO thresholds for treatment change, with consideration whether this should be age and device dependent. High quality RCT study set in primary care setting to assess impact of FeNO use on asthma control, exacerbations, ICS use and quality of life.
Expected outcomes:
At present there is a lack of adequately powered and well-designed studies showing a benefit from FeNO measurement to support its routine use in primary care for asthma monitoring in children. However, if the optimal decision thresholds and role of FeNO in asthma monitoring could be established, its ease of use, portability and reproducibility would make it a potentially important tool for guiding treatment in primary care. The RCTs here suggest it has the potential to reduce asthma exacerbations by appropriate targeting of increased ICS dose. Long-term, a targeted strategy for asthma treatment with adequate doses of ICS and a subsequent reduction in exacerbations may be cost-effective due to reduced costs of hospitalisation and serious complications.
